ClinicalTrials.gg

Hypertension clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 6,122 studies for Hypertension across more than 10 countries. 909 are recruiting or about to start. 3,896 of them are mainly about Hypertension (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 13 narrower conditions too, such as Hypertension, Pulmonary: 9,086 studies, 1,577 open.

ClinicalTrials.gov finds 12,624 studies for Hypertension. How that becomes 6,120 here

This page counts the studies the registry files under Hypertension, and those it files under no condition that list Hypertensionthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 12,624Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −2,928Filed under a narrower condition, counted on its own pageHypertension, Pulmonary 996 · Pre-Eclampsia 795 · Pulmonary Arterial Hypertension 499 · Essential Hypertension 297 · Hypertension, Pregnancy-Induced 89 · Cirrhosis, Familial, with Pulmonary Hypertension 37 · 7 more
  3. −1,324List Hypertension as a condition, but the registry did not file them under itMost often written as “Ocular Hypertension” (506), “Portal Hypertension” (239), and “Intracranial Hypertension” (76). The registry filed 16 of them under no condition at all, and the others under other conditions only, most often Ocular Hypertension (571) and Glaucoma, Open-Angle (385).
  4. −2,252Match it another way403 name it in the title, 137 in a keyword, and 1,712 by a synonym or other text the search reads.
  5. 6,120The count on this page175 of them list Hypertension in their own words; the registry filed them under no condition.

Status

Completed
3,877
Status unknown
655
Recruiting
558
Not yet recruiting
284
Terminated
279
Active, not recruiting
218

Phase

Phase 4
715
Phase 3
664
Phase 2
441
Phase 1
375
Early Phase 1
48

Where

United States
2,031
China
408
Korea, Republic of
302
Canada
286
Germany
282
United Kingdom
223

Who develops what

Add Hypertension to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 65 programs from 41 companies, 47 with this as their studies’ main aim; 13 with a live phase 3 study; 15 primary completions in the next 12 months. Compare Yuhan, Shenzhen Salubris Pharmaceuticals and Celltrion here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AmlodipineRecent, repeated
Evidence
  • NCT07704684 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3 · comparator · “Active Comparator: Amlodipine Group” · registered Jul 2026
  • NCT06646354 · hyundai pharm · Phase 3 · live · comparator · “Candesartan/Amlodipine” · registered Oct 2024
  • NCT06212648 · Shin Poong Pharmaceutical Co. Ltd. · Phase 2 · comparator · “SPC4001” · registered Nov 2022
  • NCT05103332 · Alnylam Pharmaceuticals · Phase 2 · background · “Amlodipine” · registered Oct 2021
  • NCT04974138 · Shenzhen Ausa Pharmed Co.,Ltd · Phase 4 · live · comparator · “Amlodipine besylate” · registered Jul 2021
Novartis28% of its industry studiesUS: off-patent, 49 generics marketed33 studies
LosartanRecent, repeated
Evidence
  • NCT07704697 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3 · comparator · “Active Comparator: Sacubitril/Allisartan Group” · registered Jul 2026
  • NCT06431477 · Chong Kun Dang Pharmaceutical · Phase 4 · live · comparator · “Losartan” · registered May 2024
  • NCT04074551 · Hanmi Pharmaceutical Company Limited · Phase 3 · comparator · “Losartan” · registered Aug 2019
  • NCT03897868 · Hanmi Pharmaceutical Company Limited · Phase 2 · comparator · “Losartan” · registered Mar 2019
  • NCT03666351 · Hanmi Pharmaceutical Company Limited · Phase 4 · background · “Losartan” · registered Aug 2018
Organon & Co.21% of its industry studiesUS: off-patent, 22 generics marketed22 studies
candesartanRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT06646354 · hyundai pharm · Phase 3 · live · comparator · “Candesartan/Amlodipine” · registered Oct 2024
  • NCT06212648 · Shin Poong Pharmaceutical Co. Ltd. · Phase 2 · comparator · “SPC3001” · registered Nov 2022
  • NCT04521023 · Chong Kun Dang Pharmaceutical · Phase 4 · comparator · “Candemore Plus Tab” · registered Aug 2020
  • NCT02770261 · Lotus Pharmaceutical Co., Ltd. · Phase 3 · comparator · “Candesartan32mg” · registered May 2016
  • NCT02651870 · Chong Kun Dang Pharmaceutical · Phase 3 · background · “Candesartan 16mg” · registered Jan 2016
AstraZeneca29% of its industry studies22 studies

33 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
orforglipron☆ Track3 live phase-3 studies: NCT06948422, NCT06948435, NCT06952530Eli Lilly and Company
HCP1803-4☆ Track1 live phase-3 study: NCT07660796Hanmi Pharmaceutical Company Limited
AmlodipineApproved: US☆ Track1 live phase-3 study: NCT07618806zentiva k s
baxdrostatApproved: US 2026☆ Track3 live phase-3 studies: NCT06742723, NCT07686120, NCT06268873AstraZeneca
EthanolApproved: US☆ Track2 live phase-3 studies: NCT07083765, NCT02910414Ablative Solutions, Inc.

The 5 in phase 3 with the nearest primary completion, of 65 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (15)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.QLS1410 · Qilu Pharmaceutical Co., Ltd. · Phase 2 main aimNCT07489612 QLS1410 in Participants With Uncontrolled Hypertension — primary endpoint: Change from baseline in mean seated systolic blood pressure (SBP) at week 12 · 260 enrolled
  • Dec 2026 est.tonlamarsen · Kardigan, Inc. · Phase 2 named, not the main aimNCT07511361 Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension — primary endpoint: Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions · 140 enrolled
  • Dec 2026 est.HRS-9563 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 main aimstudied with Sodium ChlorideNCT07297797 Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension — primary endpoint: Change from baseline in 24-hour mean systolic blood pressure assessed by ABPM at month 6 · 238 enrolled

12 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hypertension studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Angiotensin receptor blockers (ARBs) 12 open · Calcium channel blockers 12 open · Mineralocorticoid receptor antagonists (MRAs) 12 open · Diuretics 10 open · Thiazide diuretics 6 open

Coming up

357studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger. 40 (7%) take children under 18. 55 (10%) are for women only and 4 (1%) for men only; 139 (25%) take healthy volunteers.

Recruiting studies that take each age, of 558
AgeWomenMen
1030 (5%)28 (5%)
18381 (68%)343 (61%)
30446 (80%)403 (72%)
40473 (85%)431 (77%)
50492 (88%)450 (81%)
65480 (86%)444 (80%)
75407 (73%)379 (68%)
85313 (56%)288 (52%)

Across all 6,122 studies, recruiting or not: 36% stop at 75 or younger and 21% at 65; 9% take children; 6% are for women only and 5% for men only; 25% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hypertension studies take

Of 176 phase 1 interventional studies under Hypertension, half reached primary completion within 4 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 14 mo1–18 · 176 studies2 mo1–8 · 132 studies34 mo12–… · 44 studies
Phase 1/241 mo10–60 · 21 studies——
Phase 225 mo11–56 · 110 studies14 mo9–22 · 56 studies53 mo28–75 · 54 studies
Phase 2/323 mo10–41 · 15 studies——
Phase 321 mo12–42 · 141 studies18 mo11–29 · 95 studies39 mo19–71 · 46 studies
Phase 431 mo16–52 · 161 studies22 mo16–31 · 35 studies36 mo15–55 · 126 studies
Interventional, no phase23 mo10–42 · 1,500 studies34 mo12–55 · 95 studies23 mo10–41 · 1,405 studies
Observational38 mo17–96 · 428 studies29 mo14–45 · 81 studies44 mo17–111 · 347 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting15

Show 10 more

Newly registered41

Show 36 more

Studies

Recruiting first, then most recently updated. Showing 50 of 6,122. Browse all 6,122 → or search them.